Acute decompensated heart failure
Conditions
Interventions
switch from Carperitide to Tolvaptan within 48 hours after admission
continue Carperitide
Sponsors
Anjo Kosei Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Acute decompensated heart failure patients initially treated with low-dose Carperitide who meet all of following criteria 1) Heart failure patients diagnosed by Framingham criteria 2) Patients with refractory fluid retention 48hrs after admission in spite of loop-diuretic therapy(equivalent to >20mg frosemide dose) 3) In-hospital patients at entry 4) 20 years of age and older patients at entry 5) Patients with written informed consent 6) Paients irrespective of sex
Exclusion criteria
Exclusion criteria: 1)Patients who already have tolvaptan at entry 2) Hypernatremia(serum Na>145mEq/L) 3) Insensitivity to thurst or difficulty in water intake 4) Anuria 5) Pregnant or possibly pregnant 6) History of hypersensitivity to Tolvaptan 7) Any conditions inappropriate to this trial deemed by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Length of hospitalization, Cost of hospitalization, One-year prognosis, Time to MACE, readmission for worsening of heart failure and death from any cause) Number of hospitalizations | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in renal function, serum sodium and plasma BNP level Improvement of the signs of congestion assessed by physical examination, chest X-ray and echocardiography | — |
Countries
Japan
Contacts
Public ContactAyako Miura
Anjo Kosei Hospital Department of Cardiology
Outcome results
None listed